Original Articles
Vol. 16 (2021)

CONTRAST-ENHANCEMENT ULTRASOUND WITH MICROBUBBLES FOR SENTINEL NODE IDENTIFICATION: A CASE REPORT

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: October 15 2025
0
Views
0
Downloads

Authors

Lymph node (LN) stage remains the primary prognostic discriminant in breast cancer. Lymphatic mapping with sentinel LN (SLN) represents the gold standard for axillary staging in early breast cancer (EBC), thus identification of a new contrast agent could provide clinicians with an alternative to blue dye. AX-CES 1.2020, a prospective non-inferiority phase III trial designed to evaluate the use of Sonovue (microbubbles with sulphur hexafluoride) under contrast enhanced ultrasound (CEUS) as a SLN contrast agent. We herein present the first patient enrolled in the AX CES 1.2020 trial. In the present clinical report, CEUS-SLN was a safe and feasible technique that enhanced the same LN identified by m99Tc. Larger series are needed in order to investigate the role of CEUS-SLN in EBC and further studies could evaluate the combination of the pathological and ultrasonographic features of CEUS-SLN to predict axillary involvement.

Downloads

Download data is not yet available.

Citations

How to Cite



CONTRAST-ENHANCEMENT ULTRASOUND WITH MICROBUBBLES FOR SENTINEL NODE IDENTIFICATION: A CASE REPORT. (2025). EuroMediterranean Biomedical Journal, 16. https://doi.org/10.3269/ebmj.2021.90